Its product pipeline also includes XIAFLEX, an injectable collagenase enzyme, which is in Phase III of development for the treatment of Dupuytren?s contracture and in Phase II of development for the treatment of Peyronie?s Disease and Adhesive Capsulitis. The company markets Testim, a topical 1% testosterone gel for the treatment of hypogonadism. Overvalued 10 biotechs/pharmas? is AUXL one of them?ħ:02AM Auxilium Pharma beats by $0.12, reports revsĪuxilium Pharma AUXL Collins Stewart Neutral » Buy $23ħ:03AM Auxilium Pharma announced a 17 month safetyĪuxilium Pharma AUXL Collins Stewart Neutral $26 » $23ħ:03AM Auxilium Pharma beats by $0.08, beats onĦ Highly Shorted Stocks Being Bought Up byĪuxilium Pharmaceuticals Announces Results from Three Year CORDLESSħ:02AM Auxilium Pharma announces results from 3 yearħ:13AM Auxilium Pharma misses by $0.01, misses onĪuxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, focuses on developing and marketing products to urologists, endocrinologists, orthopedists, and primary care physicians primarily in the United States. ~ Monday! $AUXL ~ Earnings posted, pending orģ. to Present at the Cowenħ:00AM Auxilium Pharma: FDA accepts XIAFLEX supplemental biologicsħ:01AM Auxilium Pharma announces 'Encouraging' top-line 30-day dataĪuxilium's Management Presents at Lazard Capital Markets Healthcareħ:04AM Auxilium Pharma announces 30 month XIAFLEX safetyħ:04AM Auxilium Pharma announces additional Phase III XIAFLEXħ:01AM Auxilium Pharma announces 'positive' top-line data fromĩ:29AM Auxilium Pharma and Actelion announce approval ofħ:02AM Auxilium Pharma and FCB I file lawsuitħ:02AM Auxilium Pharma and GlaxoSmithKline (GSK) enter intoħ:13AM Auxilium Pharma and FCB I LLC announceĪuxilium Pharmaceuticals (AUXL), a specialty biotech that develops ![]() $AUXL - Auxilium Could Get Bought, But NotĪuxilium Pharma confirms FDA approval for XIAFLEX forħ:09AM Auxilium Pharma beats by $0.03, beats onħ:03AM Auxilium Pharma announces license agreement for theħ:31AM Auxilium Pharma presented data at the ASSHħ:54AM On The Wires (WIRES) : Auxilium Pharmaceuticalsħ:02AM Auxilium Pharma raises $50 mln in additionalĦ:03AM Auxilium Pharma receives notification of XIAFLEX PDUFAĪUXL Last Weeks annotated chart - with theĪuxilium Pharmaceuticals, Inc. Submits Application To The FDAĪuxilium Pharmaceuticals, Inc. Study Suggests Link Between Viagra And MelanomaĪuxilium Pharmaceuticals, Inc. Ih./p.php?pid=nmona&article=62707955 Auxilium Pharmaceut All rights reserved.Cowen Reiterates Market Perform On Auxilium Following Phase Have you filled out our Guestbook? If not, please do.Ĭopyright © 1997 - 2022. All of the conditions to the Offer have been satisfied, and on December 2, 2020, Endo accepted for payment, and will as promptly as practicable pay for, all shares validly tendered and not validly withdrawn.Īddress: 35 Wilbur Street, Lynbrook, NY 11563įind a problem? Please use our Feedback Page or Email us. Computershare Trust Company, N.A., the depositary and paying agent for the Offer, reported that approximately 6,159,975 shares of BioSpecifics’ common stock were validly tendered and not validly withdrawn, representing approximately 82.8% of the outstanding shares of BioSpecifics’ common stock on a fully diluted basis. (NASDAQ: BSTC) (the “Company” or “BioSpecifics”), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX® in North America, today announced the successful completion of its acquisition by Endo International plc (“Endo”) for approximately $658.2 million in equity value.Įndo’s all-cash tender offer (the “Offer”) to acquire all of the issued and outstanding shares of BioSpecifics’ common stock at a purchase price of $88.50 per share expired one minute after 11:59 p.m., New York time, on December 1, 2020. ![]() ![]() Notes: Decem– BioSpecifics Technologies Corp. The Company is with the Russell 3000 and Russell Global Indexes as part of Russell Investments' annual reconstitution of its U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord in the palm and for Peyronie's disease in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy by BioSpecifics' partner, Auxilium Pharmaceuticals, Inc. Injectable collagenase is approved for marketing as XIAFLEX (collagenase clostridium histolyticum or CCH) in the U.S. * NOTE: This security is no longer trading as of Ĭompany's Online Profile BUSINESS: BioSpecifics Technologies Corp.is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |